The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBHI.L Regulatory News (BHI)

  • There is currently no data for BHI

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Half-year Report

3 Dec 2020 07:00

RNS Number : 3423H
BMO UK High Income Trust PLC
03 December 2020
 

To: RNS

From: BMO UK High Income Trust PLC

Date: 3 December 2020

LEI: 213800B7D5D7RVZZPV45

 

 

Unaudited Interim Results

The Board of BMO UK High Income Trust PLC announces the unaudited interim results of the Company for the six month period to 30 September 2020.

 

Highlights

 

· Net asset value total return(1) per share for the six months was +15.7%, ahead of the Benchmark(2) total return of +7.0%.

 

· Ordinary share price total return for the six months was +17.9% compared to the Benchmark total return of +7.0%.

 

· B share price total return for the six months was +21.4% compared to the Benchmark total return of +7.0%.

 

· Distribution yield(1) of 6.6% on Ordinary shares and B shares at 30 September 2020, compared to the yield on the FTSE All-Share Index of 4.6%.

 

Notes:

 

1. Total Return and yield - see Alternative Performance Measures.

2. Benchmark - From launch on 1 March 2007, the Company's benchmark index was the FTSE All-Share Capped 5% Index. Following shareholder approval at the Company's AGM on 5 July 2018, the benchmark was changed to the FTSE All-Share Index.

 

 

Chairman's Statement

 

Investment performance

For the six months to 30 September 2020 the net asset value total return for both the Ordinary shares and B shares was +15.7%, significantly ahead of the +7.0% total return recorded by the FTSE All-Share Index - the benchmark.

I mentioned in my statement in the Annual report for the year to 31 March 2020 that the Manager had focused the investment portfolio with a high level of commitment behind each investment. I suggested that the portfolio was unlikely to perform in line with the benchmark index. So it has proved. Performance has also been good relative to the peer group of UK Equity Income Investment Companies as measured by the AIC. The sector recorded a net asset value total return of 9.0% over the six months to 30 September 2020.

The outperformance relative to the benchmark has been driven by two factors, excellent stock selection and the beneficial effects of gearing. The Company's borrowing facilities were utilised consistently throughout the period under review.

In numerical terms of the 8.7% points of outperformance stock and sector selection contributed 8%. In particular, excellent contributions were made by ASOS, Wizz Air and by Just Eat Takeaway, a huge beneficiary of the transition to dining at home under the pandemic restrictions.

During the period under review, stock markets around the world recovered from the lows of March as the measures imposed to counteract the spread of COVID-19 proved to be effective and controls were gradually eased. Initially in this period a number of companies took the opportunity to raise equity in order to strengthen their balance sheets and provide a buffer against poor trading and weak cash flow. Generally, such fund raisings were well supported and subsequent share price movements were very strong.

Your Manager participated in a number of these issues in the period under review, mostly notably ASOS, Compass, Beazley and Signature Aviation.

ASOS was a company we backed with additional capital at the onset of the crisis. The Manager believed ASOS would be a beneficiary of the structural shift online during the pandemic and therefore took advantage of a stock he felt was oversold. The share price has risen nearly 200% since the capital raising, confirming the Manager's view of the qualities of its business model. The Manager has also backed Compass Group, a supplier of catering to schools, business, leisure and healthcare sectors. With most sectors closed for business Compass was hit hard by the first global lockdown but with markets beginning to open and a vaccine on the horizon we have seen a sharp rebound in performance. This will be true of many companies hit hard by the pandemic. For some, the structural shift will not unwind, but for others there was clear upside with the potential return of a normalised, or at least a new normal environment.

As markets recovered there was a slight narrowing of the discount at which both the Ordinary and B shares traded. Consequently, the Share price total return for the period was +17.9% (Ordinary shares) and +21.4% (B shares).

 

Earnings, dividends and capital distributions

Another comment made in the last Chairman's statement was to highlight the significant reduction in the level of dividends being paid by UK companies. This is fully reflected in the sharp fall of 30.9% in the revenue return per share for the six months to 30 September 2020 when compared to the previous equivalent period.

The outlook for dividends in the UK remains uncertain but perhaps the nature of the uncertainty has evolved since March. Much debate now centres on when dividends will be reinstated or increased - not on by how much they will be reduced. Our investment portfolio has been insulated from the worst of the falls given our sector positioning, driven by the Manager's views on the fundamental weaknesses inherent in their business models of sector constituents. We have a very small weight in Oil & Gas and no exposure to UK high street banks and have transitioned the investment portfolio to better quality business models, with more robust balance sheets and better dividend cover. For example, within the Financial sector while high street banks have stopped paying dividends, we have seen Intermediate Capital Group, Brewin Dolphin and Phoenix Group hold or pay very similar dividends to the previous year, attesting this quality shift. These two themes have reduced the impact on our revenue account and we feel there is more we can do as we enter the second half of the financial year to continue driving upside to our forecast revenue.

It is the Board's intention to at least maintain the level of distribution to shareholders in the current financial year. The Board will utilise some revenue reserves to achieve this. Three quarterly interim dividends have so far been declared each of 1.29p per share, the same level as was paid in the previous financial year. As a reminder, following the payment of the fourth quarterly interim dividend for the year to 31 March 2020 revenue reserves per Ordinary share were 5.7p, and the annual dividend, barring unforeseen circumstances is expected to be at least 5.21p per share.

The expected annual distribution level represents a yield for Ordinary shareholders and B shareholders of 6.6% based on the share prices as at 30 September 2020. This yield compares favourably with the yield on the benchmark index of 4.6%.

 

Discount and buy backs

The Company's Ordinary share price and B share price stood at a discount to net asset value of 8.1% at 30 September 2020. Over the six-month period the price of the Company's shares traded at an average discount of 10.1% (Ordinary shares) and 9.4% (B shares).

During the period 100,000 Ordinary shares and 50,000 B shares were bought back at an average discount of 10.9% to the prevailing net asset value at the time of purchase. Subsequent to the period end, a further 350,000 Ordinary shares were bought back at an average discount of 12.4% to the prevailing net asset value at the time of purchase.

Board changes

Helen Driver and Stephen Mitchell were appointed as non-executive directors with effect from 6 May 2020. Both have considerable experience in the investment world and will bring complementary skills to your Board. James Williams, our Senior Independent Director, retired following the AGM on 27 July 2020. Following James' retirement Andrew Watkins is now our Senior Independent Director and Stephen Mitchell will chair the Engagement and Remuneration Committee.

Outlook

Markets enjoyed a period of strong returns in the first half of the Company's financial year driven by the sentiment that the COVID-19 pandemic was being brought under control and also by evidence that the corporate sector in aggregate was dealing with tough trading conditions better than anticipated.

There are now more causes for uncertainty. It appears that infection rates have risen significantly from the summer lows and governments around the world are now in a phase of reimposing lockdown measures - but on a more regionally selective basis than before.

Brexit is beginning to rear its head as the rhetoric between the UK and Europe escalates. Given the backdrop of COVID-19, Brexit has not managed to grab the same headlines, or the markets' attention as otherwise might have been anticipated. While this is the case for now, this ongoing unrest does not help the perception of the UK market, despite the fact there is a lot of value on offer. The outcome of the US Presidential election was well received by markets. The consensus was for a Biden win, which we got, but a split Senate would see a dampening of some of the more left-wing policies which would have affected markets.

With the announcement of vaccines from Pfizer, Moderna and Oxford/AstraZeneca the backdrop has again changed very sharply. The rotation out of quality growth companies into value was the sharpest seen in over two decades, which should not come as a surprise given how extended relative valuations have become since the outbreak of the pandemic. Following Pfizer's announcement, your Company's investment portfolio performed exceptionally well delivering further outperformance. The news on the approval and subsequent availability of the Pfizer vaccine is a cause for optimism but there remains some uncertainty as to how long it will take to vaccinate a significant proportion of the population. Another debate is what will the recovery look like - is there a new normal, with a drive to working from home and shopping online and does the shape of the investment landscape change? The answer is almost definitely yes, and the portfolio needs to be invested in those companies that are judged to be the winners over the coming years. So far your Company has managed the pandemic well, and the investment portfolio has the right balance to deliver over the medium-term.

 

John M Evans

Chairman

2 December 2020

 

Condensed Unaudited Statement of Comprehensive Income

For the six month period to 30 September 2020

 

Six months to 30 September 2020

 

 

 

 

Notes

Revenue

Capital

Total

 

£'000

£'000

£'000

 

 

 

 

Gains on investments held at fair value

-

12,797

12,797

Exchange differences

-

(17)

(17)

Investment income 2

1,803

-

1,803

Investment management fee 3

(105)

(245)

(350)

Other expenses

(220)

-

(220)

Profit before finance costs and taxation

1,478

12,535

14,013

 

 

 

 

Net finance costs

 

 

 

Interest on bank loans

(32)

(74)

(106)

Total finance costs

(32)

(74)

(106)

 

 

 

 

Profit before tax

1,446

12,461

13,907

Tax on ordinary activities 4

(7)

-

(7)

Profit for the period

1,439

12,461

13,900

 

 

 

 

 

 

 

 

Total comprehensive income for the period

1,439

12,461

13,900

 

 

 

 

 

 

 

 

Earnings per share 5

1.23p

10.67p

11.90p

 

 

The total column of this statement represents the Company's Income Statement and Statement of Comprehensive Income, prepared in accordance with IFRS. The supplementary revenue return and capital return columns are both prepared under guidance published by the Association of Investment Companies.

 

All revenue and capital items in the above statement derive from continuing operations.

 

All of the profit and comprehensive income for the period is attributable to the owners of the Company.

 

Condensed Unaudited Statement of Comprehensive Income

 

 

Six months to 30 September 2019

Year to March 2020*

 

 

 

 

 

 

 

Notes

Revenue

Capital

Total

Revenue

Capital

Total

 

£'000

£'000

£'000

£'000

£'000

£'000

 

 

 

 

 

 

 

Gains/(losses) on investments held at fair value

-

3,965

3,965

-

(27,431)

(27,431)

Exchange differences

-

(8)

(8)

-

-

-

Investment income 2

2,479

-

2,479

4,836

-

4,836

Investment management fee 3

(121)

(281)

(402)

(227)

(529)

(756)

Other expenses

(208)

-

(208)

(467)

-

(467)

Profit/(loss) before finance costs and taxation

2,150

3,676

5,826

 

4,142

 

(27,960)

 

(23,818)

 

 

 

 

 

 

 

Net finance costs

 

 

 

 

 

 

Interest on bank loan

(31)

(72)

(103)

(62)

(144)

(206)

Total finance costs

(31)

(72)

(103)

(62)

(144)

(206)

 

 

 

 

 

 

 

Profit/(loss) before tax

2,119

3,604

5,723

4,080

(28,104)

(24,024)

Tax on ordinary activities 4

(27)

-

(27)

(27)

-

(27)

Profit/(loss) for the period

2,092

3,604

5,696

4,053

(28,104)

(24,051)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total comprehensive income for the period

2,092

3,604

5,696

4,053

(28,104)

(24,051)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Earnings per share 5

1.78p

3.07p

4.85p

3.46p

(23.99)p

(20.53)p

 

The total column of this statement represents the Company's Income Statement and Statement of Comprehensive Income, prepared in accordance with IFRS. The supplementary revenue return and capital return columns are both prepared under guidance published by the Association of Investment Companies.

 

All revenue and capital items in the above statement derive from continuing operations.

All of the profit and comprehensive income for the period is attributable to the owners of the Company.

 

*these figures are audited.

 

 

Condensed Unaudited Statement of Financial Position

 

 

 

 

 

Notes

30 Sept

30 Sept

31 March

 

2020

2019

2020*

 

£'000

£'000

£'000

 

 

 

 

Non-current assets

 

 

 

Investments held at fair value through

profit or loss 9

109,398

126,189

92,587

 

109,398

126,189

92,587

 

 

 

 

Current assets

 

 

 

Receivables

300

471

938

Cash and cash equivalents

552

5,290

4,003

 

852

5,761

4,941

 

 

 

 

Total assets

110,250

131,950

97,528

Current liabilities

 

 

 

Payables

(519)

(1,675)

(507)

Bank Loan 10

(2,000)

-

-

 

(2,519)

(1,675)

(507)

Non-current liabilities

 

 

 

Bank loan 10

(7,500)

(7,500)

(7,500)

 

(7,500)

(7,500)

(7,500)

Total liabilities

(10,019)

(9,175)

(8,007)

Net assets

100,231

122,775

89,521

 

 

 

 

Capital Reserves

 

 

 

Share capital 11

134

134

134

Share premium

153

153

153

Capital redemption reserve

5

5

5

Buy back reserve

81,038

81,643

81,157

Special capital reserve

14,133

15,742

14,945

Capital reserves

(446)

18,801

(12,907)

Revenue reserve

5,214

6,297

6,034

Equity shareholders' funds

100,231

122,775

89,521

Net asset value per Ordinary share 12

85.94p

104.66p

76.66p

Net asset value per B share 12

85.94p

104.66p

76.66p

 

Approved by the Board, and authorized for issue, on 2 December 2020 and signed on its behalf by:

 

John M Evans, Director

 

 

*these figures are audited.

 

 

 

Condensed Unaudited Statement of Changes in Equity

for the six months to 30 September 2020

 

 

Share Capital

 

Share Premium

Capital Redemption Reserve

Buy Back Reserve

Special Capital Reserve

 

Capital Reserves

 

Revenue Reserve

 

 

Total

 

£'000

£'000

£'000

£'000

£'000

£'000

£'000

£'000

 

 

 

 

 

 

 

 

 

Balance as at 1 April 2020

134

153

5

81,157

14,945

(12,907)

6,034

89,521

Profit for the period

-

-

-

-

-

12,461

1,439

13,900

Share bought back for treasury

-

-

-

(119)

-

-

-

(119)

Dividends paid on Ordinary shares

-

-

-

-

-

-

(2,259)

(2,259)

Capital returns paid on B shares

-

-

-

-

(812)

-

-

(812)

Balance as at 30 September 2019

134

153

5

81,038

14,133

(446)

5,214

100,231

 

for the six months to 30 September 2019

 

 

Share Capital

 

Share Premium

Capital Redemption Reserve

Buy

Back Reserve

Special Capital Reserve

 

Capital Reserves

 

Revenue Reserve

 

 

Total

 

£'000

£'000

£'000

£'000

£'000

£'000

£'000

£'000

 

 

 

 

 

 

 

 

 

Balance as at 1 April 2019

134

153

5

81,643

16,540

15,197

6,433

120,105

Profit for the period

-

-

-

-

-

3,604

2,092

5,696

Dividends paid on Ordinary shares

-

-

-

-

-

-

(2,228)

(2,228)

Capital returns paid on B shares

-

-

-

-

(798)

-

-

(798)

Balance as at 30 September 2019

134

153

5

81,643

15,742

18,801

6,297

122,775

 

for the year to 31 March 2020 *

 

 

Share Capital

 

Share Premium

Capital Redemption Reserve

Buy Back Reserve

Special Capital Reserve

 

Capital Reserves

 

Revenue Reserve

 

 

Total

 

£'000

£'000

£'000

£'000

£'000

£'000

£'000

£'000

 

 

 

 

 

 

 

 

 

Balance as at 1 April 2019

134

153

5

81,643

16,540

15,197

6,433

120,105

(Loss)/Profit for the year

-

-

-

-

-

(28,104)

4,053

(24,051)

Shares bought back for treasury

-

-

-

(486)

-

-

-

(486)

Dividends paid on Ordinary shares

-

-

-

-

-

-

(4,452)

(4,452)

Capital returns paid on B shares

-

-

-

-

(1,595)

-

-

(1,595)

Balance as at 31 March 2020

134

153

5

81,157

14,945

(12,907)

6,034

89,521

\* These figures are audited

 

Condensed Unaudited Cash Flow Statement

 

Six months to

30 Sept 2020

Six months to

30 Sept 2019

Year to

31 March 2020*

 

£'000

£'000

£'000

Cash flow from operating activities

 

 

 

Profit/(loss) before tax

13,907

5,723

(24,024)

Adjustments for:

 

 

 

(Gains)/losses on investments held at fair value through profit or loss

(12,797)

(3,965)

27,431

Exchange losses

17

8

-

Interest Income

(1)

(7)

(23)

Interest received

1

7

23

Dividend income

(1,802)

(2,472)

(4,813)

Dividend income received

2,354

3,445

5,428

Decrease/(increase) in receivables

4

2

(16)

Increase/(decrease) in payables

12

1

(47)

Finance costs

106

103

206

Oversea tax suffered

(23)

(52)

(55)

Net cash inflow from operating activities

1,778

2,793

4,110

Cash flows from investing activities

 

 

 

Purchases of investments

(11,665)

(6,263)

(19,784)

Sales of investments

7,744

10,687

25,201

Net cash (outflow)/inflow from investing activities

(3,921)

4,424

5,417

Cash flows from financing activities

 

 

 

Dividends paid on Ordinary shares

(2,259)

(2,228)

(4,452)

Capital returns paid on B shares

(812)

(798)

(1,595)

Interest on bank loan

(101)

(97)

(195)

Shares purchased for treasury

(119)

-

(486)

Drawdown of loan

2,000

-

-

Net cash outflow from financing activities

(1,291)

(3,123)

(6,728)

Net (decrease)/increase in cash and cash equivalents

(3,434)

4,094

2,799

Currency losses

(17)

(8)

-

Opening net cash and cash equivalents

4,003

1,204

1,204

Closing net cash and cash equivalents

552

5,290

4,003

 

\* These figures are audited

 

Notes to the Condensed Financial Statements (unaudited)

 

1. Accounting Policies

The condensed unaudited financial statements have been prepared on a going concern basis and in accordance with IAS 34 Interim Financial Reporting and the accounting policies set out in the statutory financial statements of the Company for the year ended 31 March 2020. The condensed financial statements do not include all of the information required for full annual financial statements and should be read in conjunction with the financial statements of the Company for the year ended 31 March 2020, which were prepared under full IFRS requirements to the extent that they have been adopted by the European Union.

 

 

2. Income

 

 

30 Sept 2020

30 Sept 2019

31 March 2020

 

£'000

£'000

£'000

UK dividend income

1,735

2,162

4,485

Overseas dividend income

67

310

328

Deposit interest

1

7

23

 

 

 

 

 

1,803

2,479

4,836

 

3. The Company's investment Manager BMO Investment Business Limited receives an investment management fee of 0.65 per cent per annum of the net asset value of the Company payable quarterly in arrears.

 

4. The taxation charge for the period represents withholding tax suffered on overseas dividend income.

 

5. The earnings per share are based on the net profit/(loss) for the period and on 116,765,010 shares (period to 30 September 2019 - 117,304,847; year to 31 March 2020 - 117,123,368), being the weighted average number of shares in issue during the period.

 

6. Earnings for the six months to 30 September 2020 should not be taken as a guide to the results of the full year.

 

7. The Board has considered the requirements of IFRS 8 'Operating Segments'. The Board is of the view that the Company is engaged in a single segment of business, of investing in equity securities, and that therefore the Company has only a single operating segment. The Board of Directors, as a whole, has been identified as constituting the chief operating decision maker of the Company. The key measure of performance used by the Board to assess the Company's performance is the total return on the Company's net asset value as calculated under IFRS and therefore no reconciliation is required between the measure of profit or loss used by the Board and that contained in the condensed financial statements.

 

 

8. Dividends and capital repayments

 

 

Payment

Date

Six months to

30 Sept 2020

Six months to

30 Sept 2019

Year

to

31 March 2020

 

 

£'000

£'000

£'000

In respect of the previous period:

 

 

 

 

Fourth interim dividend at 1.34p (2019: 1.29p) per Ordinary share

 

1 May 20

 

1,151

 

1,114

 

1,114

Fourth capital repayment at 1.34p (2019: 1.29p) per B share

 

1 May 20

 

414

 

399

 

399

 

 

 

 

 

In respect of the period under review:

 

 

 

 

First interim dividend at 1.29p (2020: 1.29p) per Ordinary share

 

7 Aug 20

 

1,108

 

1,114

 

1,114

First capital repayment at 1.29p (2020: 1.29p) per B share

 

7 Aug 20

 

398

 

399

 

399

Second interim dividend (2020: 1.29p) per Ordinary share

 

 

-

 

-

 

1,114

Second capital repayment (2020: 1.29p) per B share

 

 

-

 

-

 

399

Third interim dividend (2020: 1.29p) per Ordinary share

 

 

-

 

-

 

1,110

Third capital repayment (2020: 1.29p) per

B share

 

 

-

 

-

 

398

 

 

3,071

3,026

6,047

 

A second interim dividend for the year to 31 March 2021, of 1.29p per Ordinary share, was paid on 6 November 2020 to Ordinary shareholders on the register on 2 October 2020.

 

A second quarter capital repayment of 1.29p per B share was paid on 6 November 2020 to B shareholders on the register on 2 October 2020.

 

Although these payments relate to the period ended 30 September 2020, under IFRS they will be accounted for in the six months to 31 March 2021, being the period during which they are paid.

 

 

9. Investments held at fair value through profit or loss

 

 

Listed/

Quoted

(Level 1)

£'000

 

Subsidiary/

Unlisted

(Level 3)

£'000

 

 

 

Total

£'000

Opening book cost

107,063

250

107,313

Opening unrealised losses

(14,726)

-

(14,726)

Opening valuation

92,337

250

92,587

Movement in the period:

 

 

 

Purchases at cost

11,665

-

11,665

Sales - proceeds

(7,651)

-

(7,651)

- losses on sales

(1,043)

-

(1,043)

Increase in unrealised gains

13,840

-

13,840

Closing valuation at 30 September 2020

109,148

250

109,398

Closing book cost at 30 September 2020

110,034

250

110,284

Closing unrealised losses at 30 September 2020

(886)

-

(886)

Closing valuation at 30 September 2020

109,148

250

109,398

 

Accounting standards recognise a hierarchy of fair value measurements for financial instruments which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The classification of financial instruments depends on the lowest significant applicable input, as follows:

 

· Level 1 - quoted (unadjusted) prices in active markets for identical assets or liabilities.

· Level 2 - other techniques for which all inputs that have a significant effect on the recorded fair value are observable, either directly or indirectly. The Company held no such instruments during the period under review.

· Level 3 - techniques that use inputs that have a significant effect on the recorded fair value that are not based on observable market data. The Company's investment in its subsidiary undertaking, Investors Securities Company Limited, is included in Level 3 and is valued at its net asset value.

 

There were no transfers between levels of the fair value hierarchy during the six months ended 30 September 2020.

 

10. Bank loans

 

The Company has a £7.5 million unsecured term loan from Scotiabank Europe plc until 28 September 2022 and at a fixed interest rate of 2.58 per cent per annum. The fair value of the £7.5 million term loan, calculated using a discounted cashflow technique, is not materially different from the value reflected in the Unaudited Statement of Financial Position.

 

The Company also has a £7.5 million unsecured multicurrency revolving credit facility ("RCF") with Scotiabank (Ireland) Designated Activity Company, available until 28 September 2022. £2 million of the RCF was drawn down at 30 September 2020 at an interest rate of 1.5% (30 September 2019 - £nil; 31 March 2020 - £nil).

 

 

 

 

11. Share capital

Allotted, issued and fully paid

 

 

Listed

Held in Treasury

In Issue

 

Number

£

Number

£

Number

£

Ordinary Shares of 0.1p each

 

 

 

 

 

 

Balance at 1 April 2020

102,067,144

102,067

(16,144,491)

(16,144)

85,922,653

85,923

Repurchased to be held in treasury

 

-

 

-

 

(100,000)

 

(100)

 

(100,000)

 

(100)

Balance at 30 September 2020

102,067,144

102,067

(16,244,491)

(16,244)

85,822,653

85,823

 

B Shares of 0.1p each

 

 

 

 

 

 

Balance at 1 April 2020

32,076,703

32,077

(1,217,953)

(1,218)

30,858,750

30,859

Repurchased to be held in treasury

 

-

 

-

 

(50,000)

 

(50)

 

(50,000)

 

(50)

Balance at 30 September 2020

32,076,703

32,077

(1,267,953)

(1,268)

30,808,750

30,809

Total at 30 September 2020

134,143,847

134,144

(17,512,444)

(17,512)

116,631,403

116,632

 

During the period, the Company bought back 100,000 Ordinary shares at a cost of £79,000 and bought back 50,000 B shares at a cost of £40,000 to hold in treasury (period to 30 September 2019 - nil Ordinary shares and nil B shares; year to 31 March 2020 - 405,491 Ordinary shares and 117,953 B shares).

 

At 30 September 2020 the Company held 16,244,491 Ordinary shares and 1,267,953 B shares in treasury (30 September 2019 - 15,739,000 Ordinary shares and 1,100,000 B shares; 31 March 2020 - 16,144,491 Ordinary shares and 1,217,953 B shares).

 

12. The net asset value per share is based on shareholders' funds at the period end and on 85,822,653 Ordinary shares and 30,808,750 B shares, being the number of shares in issue at the period end (30 September 2019 - 86,328,144 Ordinary shares and 30,976,703 B shares; 31 March 2020 - 85,922,653 Ordinary shares and 30,858,750 B shares).

 

13. The fair values of the Company's financial assets and liabilities are not materially different from their carrying values in the financial statements.

 

The Company's financial risk management objectives and policies are consistent with those disclosed in the Company's financial statements for the year ended 31 March 2020.

 

14. Changes in liabilities arising from financing activities

 

 

30 September

2020

31 March

2020

 

£'000

£'000

Opening net debt at beginning of period/year

7,500

7,500

Cash flows:

 

 

Drawdown of revolving credit facility

2,000

-

Closing net debt at end of period/year

9,500

7,500

 

15. Going concern

In assessing the going concern basis of accounting, the Directors have had regard to the guidance issued by the Financial Reporting Council (including that due to COVID-19) and have undertaken a rigorous review of the Company's ability to continue as a going concern and specifically in the context of the COVID-19 pandemic. As part of that review the Board has also considered the ongoing uncertainties relating to the UK's continuing trade negotiations with the EU following its departure on 31 January 2020 and does not consider that any related outcome would affect the Company's ability to continue as a going concern.

 

The Company's investment objective and policy, which is subject to regular Board monitoring processes, is designed to ensure that the Company is invested mainly in liquid, listed securities. The value of these investments exceeds the Company's liabilities by a significant margin. The Company retains title to all assets held by its custodian and has agreements relating to its borrowing facilities with which it has complied. Cash is held only with banks approved and regularly reviewed by the Manager.

 

As part of the going concern review, the Directors noted that borrowing facilities of a £7.5 million fixed term loan and a £7.5 million revolving credit facility are committed to the Company until 28 September 2022 and loan covenants are reviewed by the Board on a regular basis.

 

The Directors believe, having assessed the principal risks and other matters, including the COVID-19 pandemic and in light of the controls and review processes noted and bearing in mind the nature of the Company's business and assets and revenue and expenditure projections, that the Company has adequate resources to continue in operational existence for a period of at least twelve months from the date of approval of the financial statements. Accordingly, they continue to adopt the going concern basis in preparing the financial statements.

 

16. Related party transactions

The Directors of the Company are considered a related party. The Directors receive aggregated remuneration for services as Directors and for which there were no outstanding balances at the period end. There have been no transactions with related parties during the first six months of the current financial year that have materially affected the financial position or performance of the Company during the period and there have been no changes in the related party transactions described in the last Annual Report that could do so.

 

17. The Company's auditor, Deloitte LLP, has not audited or reviewed the Interim Report to 30 September 2020 pursuant to the Auditing Practices Board guidance on 'Review of Interim Financial Information'. These are not full statutory financial statements in terms of Section 434 of the Companies Act 2006 and are unaudited. Statutory financial statements for the year ended 31 March 2020, which received an unqualified audit report and which did not contain a statement under Section 498 of the Companies Act 2006, have been lodged with the Registrar of Companies. The condensed financial statements shown for the year ended 31 March 2020 are an extract from those financial statements. No full statutory financial statements in respect of any period after 31 March 2020 have been reported on by the Company's auditor or delivered to the Registrar of Companies.

 

 

 

 

 

 

Statement of Principal Risks and Uncertainties

 

Most of the Company's principal risks and uncertainties that could threaten its objective, strategy, future performance, liquidity and solvency are market related and comparable to those of other investment trusts investing primarily in listed securities.

 

These risks, and the way in which they are managed, are described under the heading 'Principal Risks and Uncertainties and Viability Statement' within the Strategic Report in the Company's Annual Report for the year ended 31 March 2020.

 

The Company's principal risks and uncertainties have not changed materially since the date of that report and are not expected to change materially for the remainder of the Company's financial year.

 

The principal risks identified in the Annual Report were:

 

• Financial Risk. The Company's assets consist mainly of listed equity securities and its principal financial risks are therefore market related and include market risk (comprising currency risk, interest rate risk and other price risk), liquidity risk and credit risk

 

• Investment and strategic risk

 

• Regulatory risk

 

• Operational risk

 

• Custody risk

 

These include risks in relation to failures at service providers or loss or sabotage of data through cyber threats or business continuity failure.

 

During 2020, the Board has also considered the impact of Coronavirus (COVID-19) which has increased uncertainty and volatility in markets and has impacted the value of investments. In addition the operational resilience of the Manager and the Company's other third party service providers has been considered. This is included within financial risk and operational risk.

 

 

 

 

Statement of Directors' Responsibilities in Respect of the Interim Report

 

We confirm that to the best of our knowledge:

 

· the condensed set of financial statements has been prepared in accordance with IAS 34 'Interim Financial Reporting' and give a true and fair view of the assets, liabilities, financial position and profit or loss of the Company;

· the Chairman's Statement and the Statement of Principal Risks and Uncertainties (together constituting the Interim Management Report) include a fair review of the information required by the Disclosure Guidance and Transparency Rules ('DTR') 4.2.7R, being an indication of important events that have occurred during the first six months of the financial year and their impact on the condensed set of financial statements;

· the Statement of Principal Risks and Uncertainties shown above is a fair review of the principal risks and uncertainties for the remainder of the financial year; and

· the Chairman's Statement together with the condensed set of financial statements include a fair review of the information required by DTR 4.2.8R, being related party transactions that have taken place in the first six months of the current financial year and that have materially affected the financial position or performance of the Company during that period, and any changes in the related party transactions described in the last Annual Report that could do so.

 

 

 

On behalf of the Board

 

John M Evans

Director

2 December 2020

 

 

 

 

 

Alternative Performance Measures ("APMs")

The Company uses the following APMs:

 

Discount/premium - the share price of an investment company is derived from buyers and sellers trading their shares on the stock market. This price is not identical to the net asset value (NAV) per share of the underlying assets less liabilities of the Company. If the share price is lower than the NAV per share, the shares are trading at a discount. This usually indicates that there are more sellers of shares than buyers. Shares trading at a price above NAV per share are deemed to be at a premium usually indicating there are more buyers of shares than sellers.

 

 

 

30 September 2020

31 March 2020

 

 

Ordinary Shares

B Shares

Units

Ordinary Shares

B Shares

Units

Net asset value per share

(a)

85.94p

85.94p

343.76p

76.66p

76.66p

306.64p

Share price

(b)

79.0p

79.0p

312.0p

69.5p

67.5p

273.0p

(Discount) (c=(b-a)/(a))

(c)

-8.1%

-8.1%

-9.2%

-9.3%

-11.9%

-11.0%

 

Total Return - the theoretical return to shareholders calculated on a per share basis by adding distributions paid in the period to the increase or decrease in the Share price or NAV in the period. The distributions are assumed to have been re invested in the form of shares or net assets, respectively, on the date on which the shares were quoted ex dividend.

 

The effect of reinvesting these distributions on the respective ex dividend dates and the NAV total returns and Share price total returns are shown below.

 

30 September 2020

31 March 2020

 

 

Ordinary shares/B shares

 

 

Units

 

Ordinary shares/B shares

 

 

Units

NAV per share at start of period/year

76.66p

306.64p

103.29p

409.56p

NAV per share at end of period/year

85.94p

343.76p

76.66p

306.64p

Change in the period/year

12.1%

12.1%

-25.1%

-25.1%

Impact of dividend/capital repayment reinvestments†

 

3.6%

 

3.6%

 

3.7%

 

3.7%

NAV total return

15.7%

15.7%

-21.4%

-21.4%

 

During the six months to 30 September 2020 dividends/capital repayments totalling 2.63p (Ordinary shares/B shares) and 10.52p (units) went ex-dividend. During the year to 31 March 2020 the equivalent figures were 5.16p (Ordinary shares/B shares) and 20.64p (units).

 

 

30 September 2020

31 March 2020

 

Ordinary Shares

B Shares

Units

Ordinary Shares

B Shares

Units

Share price per share at start of period/year

 

69.5p

 

67.5p

 

273.0p

 

95.0p

 

95.0p

 

373.0p

Share price per share at end of period/year

 

79.0p

 

79.0p

 

312.0p

 

69.5p

 

67.5p

 

273.0p

Change in the period/year

13.7%

17.0%

14.3%

-26.8%

-28.9%

-26.8%

Impact of dividend/capital repayment reinvestment

 

4.2%

 

4.4%

 

3.2%

 

4.0%

 

3.9%

 

4.1%

Share price total return for the period/year

 

17.9%

 

21.4%

 

17.5%

 

-22.8%

 

-25.0%

 

-22.7%

 

During the six months to 30 September 2020 dividends/capital repayments totalling 2.63p (Ordinary shares/B shares) and 10.52p (units) went ex-dividend. During the year to 31 March 2020 the equivalent figures were 5.16p (Ordinary shares/B shares) and 20.64p (units).

 

 

 

 

 

 

Yield - The total annual dividend/capital repayment expressed as a percentage of the period end share price.

 

 

30 September 2020*

31 March 2020

 

 

Ordinary Shares

B Shares

Units

Ordinary Shares

B Shares

Units

Annual dividend/capital repayment

 

(a)

 

5.21p

 

5.21p

 

20.84p

 

5.21p

 

5.21p

 

20.84p

Share price

(b)

79.0p

79.0p

312.0p

69.5p

67.5p

273.0p

Yield (c=a/b)

(c)

6.6%

6.6%

6.7%

7.5%

7.7%

7.6%

 

*Based on expected minimum annual dividend/capital repayment of 5.21 pence per share in respect of the year ending 31 March 2021.

 

Gearing - represents the excess amount above shareholders' funds of total investments, expressed as a percentage of the shareholders' funds. If the amount calculated is negative, this is a 'net cash' position and no gearing.

 

 

 

30 September 2020

£'000

31 March 2020

£'000

Investments held at fair value through profit or loss

(a)

109,398

92,587

Net assets

(b)

100,231

89,521

Gearing (c=(a/b)-1)%

(c)

9.1%

3.4%

 

 

 

 

For further information, please contact:

Philip Webster, Fund Manager 0207 628 8000

Ian Ridge, Company Secretary 0207 628 8000

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
IR DLLFBBLLFFBQ
Date   Source Headline
29th Jun 20223:55 pmRNSChange of Name
29th Jun 202212:56 pmRNSNet Asset Value(s)
29th Jun 202211:49 amRNSKepler Trust Intelligence: New Research
28th Jun 20221:04 pmRNSNet Asset Value(s)
27th Jun 20225:02 pmRNSDividend and Capital Repayment
27th Jun 20221:18 pmRNSNet Asset Value(s)
24th Jun 20221:27 pmRNSNet Asset Value(s)
23rd Jun 20224:08 pmRNSPortfolio Update
23rd Jun 202212:51 pmRNSNet Asset Value(s)
22nd Jun 20221:07 pmRNSNet Asset Value(s)
21st Jun 202212:55 pmRNSNet Asset Value(s)
20th Jun 20224:06 pmRNSNet Asset Value(s)
17th Jun 20222:37 pmRNSNet Asset Value(s)
16th Jun 20221:11 pmRNSNet Asset Value(s)
15th Jun 20221:05 pmRNSNet Asset Value(s)
14th Jun 20221:03 pmRNSNet Asset Value(s)
13th Jun 202212:54 pmRNSNet Asset Value(s)
10th Jun 20221:48 pmRNSNet Asset Value(s)
9th Jun 202212:55 pmRNSNet Asset Value(s)
9th Jun 20229:56 amRNSDoc re Annual Report & AGM
8th Jun 202212:56 pmRNSNet Asset Value(s)
7th Jun 20221:01 pmRNSNet Asset Value(s)
6th Jun 20222:09 pmRNSNet Asset Value(s)
1st Jun 20221:15 pmRNSNet Asset Value(s)
31st May 202212:56 pmRNSNet Asset Value(s)
31st May 20227:00 amRNSAnnual Financial Report
30th May 20221:43 pmRNSNet Asset Value(s)
27th May 202212:59 pmRNSNet Asset Value(s)
26th May 20222:27 pmRNSPortfolio Update
26th May 202212:47 pmRNSNet Asset Value(s)
25th May 202212:52 pmRNSNet Asset Value(s)
24th May 20221:06 pmRNSNet Asset Value(s)
23rd May 20221:21 pmRNSNet Asset Value(s)
20th May 202212:56 pmRNSNet Asset Value(s)
19th May 20221:00 pmRNSNet Asset Value(s)
18th May 202212:51 pmRNSNet Asset Value(s)
17th May 20221:06 pmRNSNet Asset Value(s)
16th May 20221:07 pmRNSNet Asset Value(s)
13th May 20221:12 pmRNSNet Asset Value(s)
12th May 202212:51 pmRNSNet Asset Value(s)
11th May 202212:56 pmRNSNet Asset Value(s)
10th May 20221:03 pmRNSNet Asset Value(s)
9th May 20221:40 pmRNSNet Asset Value(s)
6th May 202212:41 pmRNSNet Asset Value(s)
5th May 202212:53 pmRNSNet Asset Value(s)
4th May 20221:00 pmRNSNet Asset Value(s)
3rd May 20221:43 pmRNSNet Asset Value(s)
29th Apr 20221:02 pmRNSNet Asset Value(s)
28th Apr 202212:51 pmRNSNet Asset Value(s)
27th Apr 202212:56 pmRNSNet Asset Value(s)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.